How Muira Puama Became an Identity Problem

Most herb pages start with what a plant does. This one has to start with a harder question: which plant is it? "Muira puama" and "potency wood" are trade names, not botanical names, and they have been applied to more than one Amazonian species over more than a century of commerce. The material that reaches a jar is chipped or powdered bark and root-wood — the single hardest kind of botanical material to identify by eye — travelling through a wild-harvest supply chain with very little authentication anywhere along it.

That is not a footnote to the rest of this Benefits leg. It is the foundation of it. Every claim about muira puama's effect on libido, energy, mood or memory is a claim about a specific plant producing a specific chemistry, and if the plant behind the label is uncertain then the claim inherits that uncertainty whether the seller mentions it or not. So this page does the unglamorous work first: it lays out which names are in play, what is actually traded, why the usual quality signals cannot resolve it, and what follows from the evidence. The conclusion is uncomfortable in a way worth stating up front — an identity problem does not exonerate any plant. It indicts the product.


Table of Contents

  1. The Short Answer
  2. Three Botanical Names, One Trade Name
  3. Liriosma ovata and the Older Literature
  4. What Actually Gets Traded
  5. Why Woody Material Is the Hardest Case
  6. Why "Standardised To" Cannot Fix This
  7. The Inversion: Who an Identity Problem Actually Convicts
  8. What It Does to the Research Literature
  9. How Identity Would Actually Be Established
  10. What the Name Itself Does and Does Not Imply
  11. What This Page Is Not Claiming
  12. What Label Details Do and Do Not Establish
  13. Numbered Findings: What Is Not Known
  14. Key Research Papers
  15. External Resources
  16. Connections
  17. Featured Videos

The Short Answer

The species most often intended by "muira puama" is Ptychopetalum olacoides Bentham, a shrub or small tree of the Amazon basin. That is the plant named in nearly all of the modern pharmacology, and if a bottle names any species at all, this is usually the one it names.

But it is not the only plant sold under the name. Ptychopetalum uncinatum Anselmino circulates in the same trade and under the same common names. And Liriosma ovata appears throughout the older pharmacy and materia medica literature as the botanical identity of muira puama — either as a synonym for the same article or as a name for an adjacent one, depending on which source you read; the GBIF taxonomic backbone today lists it as a synonym of Dulacia inopiflora, a plant in a different genus. Brazilian usage adds marapuama and muirapuama as spellings, and regional vernacular in the Amazon attaches "muira puama" to still other woody plants that share the reputation without sharing the genus.

So the honest answer to "which plant is muira puama?" is: usually P. olacoides, sometimes P. uncinatum, historically catalogued as Liriosma ovata, and in a powdered commercial sample, frequently unverifiable. Everything else on this page is an elaboration of that sentence and of why it matters more than it sounds.

Back to Table of Contents

Three Botanical Names, One Trade Name

It helps to see the three names as answering three different questions.

Two of those three names are still in commerce, and the third is embedded in the historical record that the marketing draws on. No part of the supply chain reliably distinguishes them at the point of sale.

Back to Table of Contents

Liriosma ovata and the Older Literature

Liriosma is a real genus name in the Olacaceae grouping, and the taxonomic relationship between Liriosma and Ptychopetalum has been revised over the years in ways that are ordinary botanical business but unhelpful commercially. Two possibilities have been open:

  1. Liriosma ovata was an older name for the plant now called P. olacoides, in which case the historical drug and the modern drug are the same and nothing is lost. Current nomenclature does not support this reading.
  2. Liriosma ovata named a genuinely different, adjacent plant that was traded under the same vernacular label, in which case the nineteenth-century clinical impressions that built muira puama's reputation may have been made on material other than the species the modern laboratories studied.

GBIF lists Liriosma ovata Miers as a synonym of Dulacia inopiflora (Miers) Kuntze, an accepted species in a different genus of the same family (Olacaceae) — not of Ptychopetalum olacoides. On that listing, the old-book muira puama and the modern P. olacoides were probably different plants. Nomenclatural synonymy is ultimately settled by a monographer working with type specimens, and a database listing is not that. What matters for a reader is the consequence: the historical evidence and the modern evidence are not certainly about the same plant, and any page that treats a nineteenth-century tonic reputation as continuous with a 2003 rodent study is assuming a taxonomic identity it has not checked.

Chemists also treat Liriosma ovata as a plant in its own right. A 2015 study isolated two new sesquiterpenoid tropolone glycosides, named liriosmasides A and B, from a methanol extract of its roots, and a 2008 study isolated two new isoprenoid glycosides from its dried bark. Neither study compared the plant with Ptychopetalum.

For checking a current accepted name, the standard free reference is Kew's Plants of the World Online, with World Flora Online as a second opinion. Both show which names are currently accepted and which are treated as synonyms — but a name check resolves only the names. It says nothing whatever about which plant is in the jar on the shelf.

Back to Table of Contents

What Actually Gets Traded

The commercial article is bark and root-wood — sometimes stem-wood, sometimes a mixture, occasionally described only as "root" with no further detail. It leaves the forest as chips or short billets and reaches the consumer market as one of four things:

Layer onto that the fact that the raw material is overwhelmingly wild-harvested rather than cultivated. Wild harvest means a collector, often paid by weight, working in a forest that contains many woody plants and at least two Ptychopetalum species. It means aggregation through intermediaries, so that a single sack may not have a single botanical origin. And it means that the person who could have identified the standing plant — the collector, looking at leaves, flowers and habit — is several transactions removed from anyone who will ever ask.

Back to Table of Contents

Why Woody Material Is the Hardest Case

Authenticating a herb usually leans on a hierarchy of methods, and woody bark defeats them in order.

  1. Whole-plant morphology is the gold standard and is unavailable by definition — nobody ships the tree.
  2. Macroscopic examination of the drug works reasonably well for a leaf, a flower or a whole root, all of which retain diagnostic shape. Bark chips retain far less, and two congeneric barks may be macroscopically indistinguishable even to an experienced pharmacognosist.
  3. Microscopy of powdered material is a genuine skill and a genuine tool, and for a well-characterised drug with a published anatomical description it can be decisive. For muira puama it is weakened twice: powdered woody tissue offers fewer diagnostic cell types than powdered leaf, and the comparative anatomy needed to separate P. olacoides from P. uncinatum in powder is not something a supplement buyer can look up.
  4. Organoleptic checks — taste, smell, fracture — are what the traditional trade actually relied on. They are better than nothing and are hopeless against a congener.

There is a second, quieter problem. Even if the species is right, the plant part may not be what the label says, and part substitution is one of the standard ways a herbal claim goes wrong. A root result cited for a bark preparation is a different intervention, exactly as an extract result cited for a tea is. Muira puama's own literature is not always explicit about which woody part was extracted, and commercial material is frequently described as "bark and root" as if the two were interchangeable. They may be. Nobody has demonstrated that they are.

Back to Table of Contents

Why "Standardised To" Cannot Fix This

This is the single most important technical point on the page, and it is the one most often got backwards.

A marker-compound assay — "standardised to X% beta-sitosterol", "assayed for total sterols", "HPLC-verified" — is a potency check, not an identity check. It tells you how much of a chosen compound is present in the material you sent to the laboratory. It cannot tell you which plant the material came from unless the marker compound occurs in that plant and in essentially nothing else you might plausibly have been sold.

Muira puama fails that condition comprehensively, and it fails it worst for exactly the compounds most likely to appear on a certificate of analysis:

The general rule this illustrates is worth carrying to every other herb: where two candidate plants share the marker, "standardised to X" says nothing about identity. Only sequence-based methods — DNA barcoding of an appropriate region — discriminate between species that share their chemistry. A certificate of analysis reporting a marker in a genus with a commercially traded congener is a document that looks like verification and is not one.

This is why an unverified product stays unverified even when it arrives with paperwork, and it is why the phrase "third-party tested" needs a follow-up question: tested for what? Heavy metals and microbial limits are worth having and are not identity. Identity is a separate test that almost nothing on this shelf has had.

Back to Table of Contents

The Inversion: Who an Identity Problem Actually Convicts

There is a standard move in herbal writing that runs like this: a herb was blamed for a harm, later analysis suggested the implicated material was a different, substituted species, therefore the herb is exonerated. The move is often factually correct about the substitution, and it is almost always deployed in the wrong direction.

Apply it honestly to muira puama and it inverts:

Two other herbs on this site illustrate the same logic from the opposite end, and it is worth seeing that muira puama is not being singled out. Epimedium is traded as a genus with many species of differing chemistry, and its product-quality page reaches the same conclusion by the same route. Tongkat Ali has the additional problem of a famous name attached to material that is often not the plant at all. The pattern is a property of the botanical libido shelf, not of one plant.

Back to Table of Contents

What It Does to the Research Literature

An identity problem is not only a consumer problem. It propagates into the evidence base in three specific ways, and knowing them changes how you read a citation.

1. Voucher specimens are the fix, and they are invisible to readers. Good ethnopharmacology deposits a voucher — a pressed, catalogued specimen in a named herbarium — so that a later worker can check what was actually extracted. The Brazilian group behind most of the muira puama pharmacology worked in the tradition that does this, and their papers name P. olacoides specifically. That is a real point in their favour and it is why this Benefits leg treats their findings as findings about a known plant. But a reader who encounters the result second-hand, in a supplement blog or a marketing page, has no way to know whether the underlying paper vouchered its material or bought a bag of powder.

2. Negative and inconsistent results become uninterpretable. When two laboratories disagree about a woody herb with a congener in trade, there are now at least three explanations rather than one: real biological variability, methodological difference, or different plants. That third possibility is rarely testable after the fact, and it makes an already thin literature harder to synthesise.

3. Citation drift carries the ambiguity forward while stripping the caveat. A paper says "ethanol extract of Ptychopetalum olacoides bark, voucher deposited." A review says "muira puama extract." A marketing page says "muira puama." A shopper reads "muira puama" and buys a powder of unknown species. Nothing false was said at any step, and the specificity that made the original claim meaningful evaporated in three moves. This is the reason the pages in this leg label the provenance of a finding at the finding rather than once in a preamble — a reader who arrives mid-page, or who lifts a single sentence, cannot carry away an unlabelled version.

Back to Table of Contents

How Identity Would Actually Be Established

It is easy to describe a problem and leave the reader with nothing but doubt. The more useful move is to say precisely what would settle it — because the tools exist, they are neither exotic nor expensive, and the reason they have not been applied here is that nobody has chosen to pay for it.

  1. DNA barcoding of the plastid and nuclear regions used for plant identification — rbcL and matK as the standard plant barcodes, with the nuclear ribosomal ITS2 region often added because it discriminates better between close congeners. GenBank already holds rbcL, matK, trnL and psbA-trnH sequences for P. olacoides, most from vouchered specimens, but none for P. uncinatum and no ITS2 sequence for either, so the two traded species cannot yet be told apart by barcode. Completing that reference set from vouchered material is the prerequisite, and it is a modest project, not a moonshot.
  2. Next-generation sequencing metabarcoding for mixed and multi-ingredient products, which can report every plant genus present in a capsule rather than confirming or denying one. This is the method that has repeatedly found declared ingredients missing and undeclared ones present across the wider supplement market.
  3. Published comparative microscopy of the powdered bark and root-wood of both traded species, so that a competent analyst without a sequencer has something to compare against.
  4. A pharmacopoeial monograph with an identity test, not merely a purity and potency test. A monograph is what converts all of the above from a research finding into a routine quality gate.
  5. Chemometric fingerprinting — a full chromatographic profile compared against vouchered reference material, rather than a single marker peak. Weaker than sequencing for identity, but far stronger than a one-compound assay, and achievable with equipment a contract laboratory already owns.

None of these has been systematically applied to the commercial muira puama supply that we can find published. That is the finding. It is not that the plant failed a test; it is that the test has not been run, and the difference between those two statements is one this whole Benefits leg is built on.

Back to Table of Contents

What the Name Itself Does and Does Not Imply

Some common names smuggle in an implication the plant does not earn, and it is worth checking directly rather than assuming. Here the check comes back mostly clear, with one narrow exception, and reporting a clear result is as much a part of accuracy as reporting a bad one.

Back to Table of Contents

What This Page Is Not Claiming

Refusing to overstate runs in both directions, and it would be easy to read this page as darker than it is. Several things are not being alleged, and a reader arriving from other herb pages may reasonably wonder about each.

The single concrete adulteration hazard on this shelf is a different one entirely — undeclared prescription erectile-dysfunction drugs in sexual-enhancement supplements — and it is dealt with in detail on the dose and safety page, because it is a category risk rather than a botany problem.

Back to Table of Contents

What Label Details Do and Do Not Establish

Given all of the above, what a label or certificate can establish is narrow. Nothing below guarantees the right plant. Each item shifts the odds, and some do more work than others.

  1. A binomial and a plant part on the label. "Ptychopetalum olacoides root bark" is a checkable claim; "muira puama extract" is not. This is the highest-value single filter, not because the label is verified but because a company willing to commit to a species in print has taken on a liability that a company printing a trade name has avoided.
  2. Chipped bark or wood versus powder. For raw material, chips are the only form in which any morphological check is possible at all.
  3. What a certificate of analysis actually tests. Heavy metals, microbial limits and a marker assay are all worth having. None of them is an identity test. A certificate that does not name a species-level identity method leaves identity unestablished.
  4. Proprietary blends are unquantified. A blend that does not state the muira puama weight says nothing about dose, and a blend is also where undeclared pharmaceuticals have historically turned up in this category.
  5. Independent certification has limits. Independent third-party testing programmes check contamination and label-quantity accuracy, not species identity, and they operate on very few products in this niche. Their absence is the normal case.
  6. Whether the vendor confirmed species identity, and how. A vendor’s answer to that question is informative either way, including when there is no answer.

Back to Table of Contents

Numbered Findings: What Is Not Known

The following are stated as results, not as gaps for the reader to infer. Each is a thing that could be known and is not.

  1. The proportion of commercial "muira puama" that is P. olacoides is unknown. No published market survey using species-level identification has been located.
  2. Whether P. uncinatum is pharmacologically equivalent is unknown. It has not been studied alongside P. olacoides in the same model at the same dose.
  3. Liriosma ovata is listed by GBIF as a synonym of Dulacia inopiflora, not of a Ptychopetalum species. Consequently the continuity between the historical drug and the modern one is unestablished, and the two were probably different plants.
  4. No validated marker exists that discriminates the traded species. The commonly assayed constituents are pan-plant compounds.
  5. No reference DNA barcode exists for P. uncinatum. GenBank holds rbcL, matK, trnL and psbA-trnH sequences for P. olacoides, most from vouchered specimens, but none for P. uncinatum (GenBank search, November 2026), so the two traded species cannot yet be told apart by barcode.
  6. Bark, root-bark and stem-wood have not been compared for constituent profile or activity, so part substitution cannot be assessed.
  7. Wild-harvest chain of custody is undocumented in the published literature, including the number of intermediaries and whether sacks are aggregated across collectors.
  8. No pharmacopoeial identity monograph with a species-discriminating test has been located for muira puama.
  9. The sustainability position is also unquantified. The article is wild-harvested bark and root-wood from a slow-growing woody plant, which is the harvest pattern most likely to be destructive, and no population assessment has been located. That is a real unknown and it is being flagged rather than either alarmed about or waved away.

Back to Table of Contents

Key Research Papers

Most citations below link a PubMed topic search rather than a fixed record, so that you see the current literature on the question rather than one paper chosen for you; the four papers that could be verified record by record end in their PubMed PMID. Where metadata could not be verified with confidence, that is stated explicitly rather than papered over.

  1. Siqueira IR, Fochesatto C, da Silva AL, Nunes DS, Battastini AM, Netto CA, Elisabetsky E. "Ptychopetalum olacoides, a traditional Amazonian 'nerve tonic', possesses anticholinesterase activity." Pharmacology, Biochemistry and Behavior, 2003;75(3):645–650. PubMed PMID: 12895682 — cited here for its identification practice rather than its result: the material is named to species and characterised as an ethanol extract, which is what makes the finding attributable to a known plant.
  2. Bucek EU, Fournier G, Dadoun H. "Volatile constituents of Ptychopetalum olacoides root oil." Planta Medica, 1987;53(2):231. PubMed PMID: 17269009 — an early analysis of the aromatic fraction of the root. Relevant to identity because a volatile profile is a candidate fingerprint, and because it is explicitly a root analysis in a trade that sells bark, root and stem interchangeably.
  3. Chemistry of Ptychopetalum diterpenoids, including ptychonal. PubMed topic search — the diterpene series is the most structurally distinctive chemistry reported from the genus and therefore the most promising candidate for a genuine identity marker. We have deliberately not attached specific author or journal metadata to this entry: the primary reports are hard to verify from secondary sources, and a confident citation here would be a guess.
  4. Ma J, Pawar RS, Grundel E, Mazzola EP, et al. "Sesquiterpenoid tropolone glycosides from Liriosma ovata." Journal of Natural Products, 2015;78(2):315–319. PubMed PMID: 25587934 — liriosmasides A and B from the roots; evidence that L. ovata is studied as a plant in its own right.
  5. Picerno P, Mencherini T, Rastrelli L, Piccinelli A, Aquino R. "Isoprenoid glycosides from Liriosma ovata." Journal of Natural Products, 2008;71(2):265–268. PubMed PMID: 18197604 — new isoprenoid glycosides from the dried bark.
  6. Ptychopetalum species and their distribution in trade. PubMed topic search — the congener is thinly represented in the indexed literature, which is itself the point. A plant sold under the same name as a much-studied relative, with almost no literature of its own, is the definition of an unverifiable substitution.
  7. DNA barcoding for herbal identification. PubMed topic search — the methodological literature that establishes ITS2, rbcL and matK as workable identity tools for commercial botanicals. Read this to see how routine the technique now is, which is what makes its absence here a choice rather than a limitation.
  8. Metabarcoding surveys of commercial herbal products. PubMed topic search — the body of work that repeatedly finds declared species absent and undeclared species present across supplement markets. None of it is specific to muira puama; all of it is the base rate against which an unverified Amazonian bark powder should be judged.
  9. Marker-compound standardisation and its limits. PubMed topic search — the pharmacognosy literature distinguishing potency assays from identity tests, which is the technical basis for this page's central argument.
  10. Beta-sitosterol distribution across plants. PubMed topic search — sufficient to show why a beta-sitosterol assay identifies "plant" and not "this plant."
  11. Amazonian medicinal bark harvest and sustainability. PubMed topic search — general literature on the harvest pattern muira puama belongs to; no population assessment specific to Ptychopetalum was located.
  12. Pharmacognostic authentication of powdered bark drugs. PubMed topic search — the methods literature behind the claim that powdered woody material is the hardest case for microscopy.

Back to Table of Contents

Back to Table of Contents

External Resources

Back to Table of Contents

Connections

Back to Table of Contents